Sambucus nigra agglutinin III (SNA-III)

Sambucus nigra agglutinin III (SNA-III) is a lectin isolated from elderberry, characterized by its specific binding to carbohydrate structures. This interaction enables SNA-III to agglutinate cells and potentially influence cellular communication via glycoprotein binding.

Origin & History

Sambucus nigra agglutinin III (SNA-III) is a lectin protein isolated from elderberry seeds, extracted via affinity chromatography. It is biochemically distinct from other elderberry lectins, containing approximately 21% carbohydrate by weight.

Historical & Cultural Context

There is no information on the traditional or historical use of SNA-III in the available research. This lectin is primarily studied for its biochemical properties.

Health Benefits

• Limited research prevents specific health benefit claims for SNA-III. • SNA-III's binding to carbohydrate structures indicates potential for agglutinating cells. • Glycoprotein binding suggests possible roles in cellular communication. • Preliminary studies suggest carbohydrate-binding specificity. • Biochemical characterization provides foundational understanding.

How It Works

SNA-III specifically binds to particular carbohydrate structures on cell surfaces and within the extracellular matrix. This carbohydrate-binding specificity facilitates the agglutination of cells and interactions with glycoproteins. Through these binding activities, SNA-III influences cellular recognition and communication pathways, potentially modulating cell-to-cell adhesion and signaling processes.

Scientific Research

There are no human clinical trials, randomized controlled trials, or meta-analyses available for SNA-III. The existing literature is limited to basic biochemical characterization studies.

Clinical Summary

Current scientific literature presents limited human clinical research specifically investigating Sambucus nigra agglutinin III (SNA-III). Preliminary in vitro studies indicate SNA-III's ability to agglutinate cells and bind to specific carbohydrate structures. Definitive health benefits or therapeutic applications in humans remain unquantified, with no large-scale clinical trials available to establish efficacy or safety profiles.

Nutritional Profile

Sambucus nigra agglutinin III (SNA-III) is a type-2 ribosome-inactivating lectin protein isolated from elderberry (Sambucus nigra) bark; it is a carbohydrate-binding protein that selectively recognizes sialylated glycoproteins and N-acetylneuraminic acid residues on cell surfaces, contributing to elderberry hemagglutinating and antiviral activity through interference with viral surface glycoprotein binding.

Preparation & Dosage

No clinically studied dosage ranges for SNA-III are documented. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

N-acetylgalactosamine, elderberry extract, glycoproteins

Safety & Interactions

Due to the extremely limited human research on Sambucus nigra agglutinin III (SNA-III), comprehensive safety profiles and potential side effects are not established. Information regarding specific drug interactions, contraindications, or safety during pregnancy and lactation is currently unavailable. Individuals should exercise extreme caution and consult a healthcare professional before considering any use of SNA-III.